Rose JW, Burns JB et al. Daclizumab phase II trial in relapsing and remitting multiple sclerossi.MRI and clinical results. Neurology 2007; 69:785-789.
Daclizumab binds to the alpha chain (CD25) of interleukin 2 receptor (IL2R) which is involved in activation of T and B cells. Currently its approved for renal allograft rejection.
Subjects had RRMS with EDSS 1-6.5, withone relapse in previous year and failed IFN therapy with at least 2 GD+ lesions on one or more of the baseline scans. 11 patients were studied. AE's included severe UTI's severe relapse at time of infusion, transient thrombocytopenia (while also receiving Bactrim). Study shows promise of daclizumab as monotherapy for MS.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment